CTLA4 and urinary bladder carcinoma: Though the signature was only significantly associated with ICI-related biomarkers like TNFRSF9, instead of CTLA4, LAG3, HAVCR2 and PDCD1, thus proving that the efficacy of immunotherapy still presents an underprivileged position within the treatment of bladder cancer.